HER2+ Breast Cancer

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

Aditya Bardia, MD, MPH, FASCO, discusses how the FDA approval of T-DXd for HER2-low/-ultralow metastatic breast cancer has affected the treatment paradigm.

ARX788 was safe and effective in HER2+ advanced breast cancer after disease progression on 1 line of a trastuzumab-based regimen.

The CHMP has recommended the approval of trastuzumab deruxtecan for HER2-low or HER2-ultralow metastatic breast cancer.

Kelly E. McCann, MD, PhD, discusses how novel ADCs and targeted therapies could improve treatment strategies in HER2-positive breast cancer.

Neoadjuvant atezolizumab plus trastuzumab, pertuzumab, and abbreviated epirubicin generated pCRs in patients with early HER2-positive breast cancer.

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

KN026 plus docetaxel elicited durable responses and a manageable safety profile in patients with recurrent/metastatic HER2-positive breast cancer.

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

The FDA accepted a BLA seeking the approval of the pertuzumab biosimilar HLX11 for HER2-positive breast cancer.

The FDA has approved a companion diagnostic for trastuzumab deruxtecan in hormone receptor–positive, HER2-ultralow metastatic breast cancer.

Dr. Clifton and Dr. Gandhi review the EMBER trial program, discussing study designs, key findings from phase 1b and EMBER-3 trials of imlunestrant-based combinations, and insights into efficacy, safety, and subgroup outcomes in estrogen receptor–positive/HER2-negative (ER+/HER2–) advanced breast cancer (ABC).

The FDA approved T-DXd for unresectable/metastatic HR+, HER2-low/-ultralow breast cancer that progressed on endocrine therapy in the metastatic setting.

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Dr. Gandhi and Dr. Clifton discuss the evolving role of oral selective estrogen receptor degraders (SERDs) in the treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer, considering patient characteristics, clinical scenarios, and the landscape of approved and investigational agents, including elacestrant, imlunestrant, and camizestrant.

Dr. Gandhi and Dr. Clifton explore the prevalence and mechanisms of resistance to first-line endocrine therapy combined with CDK4/6 inhibitors in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.

An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.

Nicole Odzer discusses the utility of ERBB2 copy number ratio as a predictive biomarker in HER2+ breast cancer.

Ian Krop, MD, PhD, discusses SHR-A1811, a third-generation antibody-drug conjugate for HER2-positive breast cancer.

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis that outlined associations between HER2-low breast cancer subtype and clinical outcomes.

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

Dr. Clifton and Dr. Gandhi discuss the critical role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer, and its impact on prognosis and treatment decision-making.

Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.

Alberto Montero, MD, MBA, CPHQ, discusses data with the combination of zanidatamab and evorpacept in HER2-positive and HER2-low metastatic breast cancer.